Drug Trial Radar · NCT07104500
VK2735 for Weight Management Phase 3
Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
4,500
Planned (sponsor's estimate)
Start
Jun 23, 2025
Primary completion
Jul 1, 2027
Study completion Aug 1, 2027
Sponsor
- Lead sponsor
- Viking Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
Conditions
- Weight Loss
Interventions
VK2735Drug
VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatmentTime frame: 78 Weeks
Locations
137 sites in 2 countries. Site status is shown where the registry gives one.
Viking Clinical Site #1037
Birmingham, Alabama
Viking Clinical Site #1064
Birmingham, Alabama
Viking Clinical Site #1128
Huntsville, Alabama
Viking Clinical Site #1081
Mobile, Alabama
Viking Clinical Site #1005
Chandler, Arizona
Viking Clinical Site #1017
Flagstaff, Arizona
Viking Clinical Site #1018
Peoria, Arizona
Viking Clinical Site #1135
Scottsdale, Arizona
Viking Clinical Site #1019
Tucson, Arizona
Viking Clinical Site #1036
Little Rock, Arkansas
Viking Clinical Site #1071
Chula Vista, California
Viking Clinical Site #1070
Escondido, California
Viking Clinical Site #1054
Huntington Park, California
Viking Clinical Site #1014
Lake Forest, California
Viking Clinical Site #1129
Lemon Grove, California
Viking Clinical Site #1051
Lincoln, California
Viking Clinical Site #1050
Long Beach, California
Viking Clinical Site #1055
Los Angeles, California
Viking Clinical Site #1078
Manteca, California
Viking Clinical Site #1053
Montclair, California
Viking Clinical Site #1068
Panorama City, California
Viking Clinical Site #1132
Rolling Hills Estates, California
Viking Clinical Site #1131
San Diego, California
Viking Clinical Site #1104
Santa Maria, California
Viking Clinical Site #1052
Spring Valley, California
Viking Clinical Site #1109
Tustin, California
Viking Clinical Site #1067
Van Nuys, California
Viking Clinical Site #1079
Walnut Creek, California
Viking Clinical Site #1119
Denver, Colorado
Viking Clinical Site #1123
Washington D.C., District of Columbia
Viking Clinical Site #1013
Clearwater, Florida
Viking Clinical Site #1121
Clearwater, Florida
Viking Clinical Site #1003
Cooper City, Florida
Viking Clinical Site #1112
DeLand, Florida
Viking Clinical Site #1107
Delray Beach, Florida
Viking Clinical Site #1083
Fort Myers, Florida
Viking Clinical Site #1058
Jacksonville, Florida
Viking Clinical Site #1076
Lakeland, Florida
Viking Clinical Site #1060
Lakewood Rch, Florida
Viking Clinical Site #1117
Miami, Florida
Showing 40 of 137 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.